ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
(WorldNews Europe)

Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission confirmed to be targeted for 4Q:19, commercial planning underway Nolasiban is a novel therapy and the first therapy of its kind to improve clinical pregnancy and live birth rates in women undergoing IVF Geneva, Switzerland and Boston, MA - October 3, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today...